The FDA has resumed issuing complete response letters (CRLs) to pharmaceutical companies after citing a renewed focus on transparency, according to reporting on newly posted decision letters. The shift follows a pause tied to an internal governance discussion, and comes as multiple late-stage programs face manufacturing, labeling, or clinical package issues.